CTOR
CITIUS ONCOLOGY, INC.
$0.6999
-2.79%
$66.9M
No data for this timeframe.
Vol
Market Cap$66.9M
Cap SizeMicro Cap
Inst. Holders3 funds
Inst. Value$620.7K
Inst. Activity2 buys / 1 sells
SEC Reports5
Recent Activity
Jun 8, 2026
SEC
Citius Oncology's S-3 registration (File No. 333-296360) became effective on June 5, 2026, enabling the resale of up to
EFFECT — Impact 7/10
Jun 1, 2026
SEC
Citius Oncology issued a press release highlighting Phase 1 data from an investigator-initiated study of LYMPHIR (denile
8-K — Impact 4/10
May 29, 2026
SEC
Citius Oncology filed an S-3 registration statement to register 32,931,482 shares of common stock for resale by selling
S-3 — Impact 7/10
Inst.
VANGUARD GROUP INC — DOUBLED
596,997 shares ($597.0K)
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
23,515 shares ($23.5K)
May 20, 2026
earnings_calendar
CTOR Q2 2026 Earnings Scheduled — 2026-05-20
Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$4.00 (Sep 2025)
Current $0.6999
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 23, 2025 | Maxim Group | UPGRADE | Hold → Buy |
| May 23, 2025 | Maxim Group | DOWNGRADE | Buy → Hold |
| Nov 27, 2024 | Maxim Group | INITIATE | Buy |
| Aug 13, 2024 | EF Hutton | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 | $-0.05 — $-0.05 | 38% YoY | 1 |
| Next Q | $-0.19 ▼ -72.7% | $-0.19 — $-0.19 | -217% YoY | 1 |
| Current FY | $-0.60 ▼ -215.8% | $-0.60 — $-0.60 | -76% YoY | 1 |
| Next FY | $0.10 ▼ -74.4% | $0.10 — $0.10 | 117% YoY | 1 |
Latest Reports
BEARISH
EFFECT
7/10
Citius Oncology's S-3 registration (File No. 333-296360) became effective on June 5, 2026, enabling the resale of up to
Jun 8, 2026
NEUTRAL
8-K
4/10
Citius Oncology issued a press release highlighting Phase 1 data from an investigator-initiated study of LYMPHIR (denile
Jun 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $597.0K | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $23.5K | NEW |
| BANK OF AMERICA CORP | $214.00 | NEAR_EXIT |
3 institutional holders with $620.7K total value (620,726 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 596,997 | $597.0K | 96.2% | DOUBLED +231.4% |
| 2 | TWO SIGMA INVESTMENTS, LP | 23,515 | $23.5K | 3.8% | NEW |
| 3 | BANK OF AMERICA CORP /DE/ | 214 | $214.00 | 0.0% | NEAR_EXIT -96.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 180,168 | 596,997 | +231.4% | $597.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 23,515 | — | $23.5K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 55,900 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 180,168 | — | $365.7K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 55,900 | — | $113.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 8,571 | 264 | -96.9% | $536.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 15,423 | 55 | -99.6% | $112.00 | 2025-Q3 |
| UBS Group AG | TRIM | 49,745 | 15,423 | -69.0% | $67.1K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 160 | 8,571 | +5256.9% | $37.3K | 2025-Q2 |
| UBS Group AG | DOUBLED | 24,805 | 49,745 | +100.5% | $46.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 11,196 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 22,699 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 1,632 | 24,805 | +1419.9% | $28.5K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 22,699 | — | $26.1K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 11,196 | — | $12.9K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 2 neutral. Avg impact: 5.6/10.
BEARISH
EFFECT
7/10
Citius Oncology's S-3 registration (File No. 333-296360) became effective on June 5, 2026, enabling
Jun 8, 2026
NEUTRAL
8-K
4/10
Citius Oncology issued a press release highlighting Phase 1 data from an investigator-initiated stud
Jun 1, 2026
BEARISH
S-3
7/10
Citius Oncology filed an S-3 registration statement to register 32,931,482 shares of common stock fo
May 29, 2026
MIXED
8-K
6/10
Citius Oncology reported fiscal Q2 2026 (March 31, 2026) net product revenue of $1.7M, down from $3.
May 15, 2026
NEUTRAL
EFFECT
4/10
CITIUS ONCOLOGY, INC. (CTOR) has announced the effectiveness of its shelf registration statement (Fi
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$4.00 mean target (Sep 2025)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.6999 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.05 | $-0.05 | 37.5% | — | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.19 | $-0.19 | $-0.19 | -216.7% | -72.7% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-09-30 |
$-0.60 | $-0.60 | $-0.60 | -76.5% | -215.8% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-09-30 |
$0.10 | $0.10 | $0.10 | 116.7% | -74.4% | 0↑ 1↓ | $0.1B | 357.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $0.000 | -0.050 |
| 30d ago | $0.000 | -0.050 |
| 60d ago | $0.000 | -0.050 |
| 90d ago | $0.000 | -0.050 |
2 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 23, 2025 | Maxim Group | UPGRADE | Hold | Buy |
| May 23, 2025 | Maxim Group | DOWNGRADE | Buy | Hold |
| Nov 27, 2024 | Maxim Group | INITIATE | — | Buy |
| Aug 13, 2024 | EF Hutton | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
earnings_calendar
CTOR Q2 2026 Earnings Scheduled — 2026-05-20
May 13, 2026
earnings_calendar
CTOR Q2 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
CTOR Q2 2026 Earnings Scheduled — 2026-05-12